Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H13F3OSi |
| Molecular Weight | 246.301 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[Si](C)(C)C1=CC=CC(=C1)C(=O)C(F)(F)F
InChI
InChIKey=GAPOASFZXBWUGS-UHFFFAOYSA-N
InChI=1S/C11H13F3OSi/c1-16(2,3)9-6-4-5-8(7-9)10(15)11(12,13)14/h4-7H,1-3H3
| Molecular Formula | C11H13F3OSi |
| Molecular Weight | 246.301 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Originator
Approval Year
Sample Use Guides
Pharmacokinetics, pharmacodynamics, and tolerance of zifrosilone were studied in a double-blind, sequential, single-escalating-dose, randomized panel design. Each panel consisted of six subjects, with four subjects receiving zifrosilone (10, 30, 60, 90, 120, 150, 200, 250, and 300 mg orally) and two subjects receiving matching placebo.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:03:33 GMT 2023
by
admin
on
Sat Dec 16 17:03:33 GMT 2023
|
| Record UNII |
6275788O83
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C47792
Created by
admin on Sat Dec 16 17:03:34 GMT 2023 , Edited by admin on Sat Dec 16 17:03:34 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
7210
Created by
admin on Sat Dec 16 17:03:34 GMT 2023 , Edited by admin on Sat Dec 16 17:03:34 GMT 2023
|
PRIMARY | |||
|
C082826
Created by
admin on Sat Dec 16 17:03:34 GMT 2023 , Edited by admin on Sat Dec 16 17:03:34 GMT 2023
|
PRIMARY | |||
|
C82222
Created by
admin on Sat Dec 16 17:03:34 GMT 2023 , Edited by admin on Sat Dec 16 17:03:34 GMT 2023
|
PRIMARY | |||
|
132236-18-1
Created by
admin on Sat Dec 16 17:03:34 GMT 2023 , Edited by admin on Sat Dec 16 17:03:34 GMT 2023
|
PRIMARY | |||
|
SUB00154MIG
Created by
admin on Sat Dec 16 17:03:34 GMT 2023 , Edited by admin on Sat Dec 16 17:03:34 GMT 2023
|
PRIMARY | |||
|
100000079416
Created by
admin on Sat Dec 16 17:03:34 GMT 2023 , Edited by admin on Sat Dec 16 17:03:34 GMT 2023
|
PRIMARY | |||
|
6275788O83
Created by
admin on Sat Dec 16 17:03:34 GMT 2023 , Edited by admin on Sat Dec 16 17:03:34 GMT 2023
|
PRIMARY | |||
|
EE-17
Created by
admin on Sat Dec 16 17:03:34 GMT 2023 , Edited by admin on Sat Dec 16 17:03:34 GMT 2023
|
PRIMARY | |||
|
DTXSID80157445
Created by
admin on Sat Dec 16 17:03:34 GMT 2023 , Edited by admin on Sat Dec 16 17:03:34 GMT 2023
|
PRIMARY | |||
|
60811
Created by
admin on Sat Dec 16 17:03:34 GMT 2023 , Edited by admin on Sat Dec 16 17:03:34 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
